Exploring underlying mechanisms of paediatric growth disorders using human ex vivo growth plates.

Exploring underlying mechanisms of paediatric growth disorders using human ex vivo growth plates. - Growth plate collection during routine epiphysiodesis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52513

Enrollment

100

Registered

2020-07-30

Start date

2020-10-23

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tall stature

Interventions

None listed

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Male or female pediatric patients ( 205 cm (boys) or > 185 cm (girls), and/or evidence of syndromic condition with predisposition for tall stature. Male or female pediatric patients undergoing PE because of idiopathic or post-traumatic limb length discrepancy or transgender patients (male to female) who have a predicted adult height in the normal male range but choose to undergo epiphysiodesis to prevent female tall stature.

Exclusion criteria

Exclusion criteria: General or other standard contra-indications for PE surgery. Inability to read Dutch and/or verbalize understanding of the study information

Design outcomes

Primary

Measure	Time frame
1. Can we harvest viable growth plate tissue from patients undergoing routine percutaneous epiphysiodesis? 2. Can we use these growth plate biopsies to make ex vivo explant cultures, perform histology, characterize molecular processes from RNA and DNA of different cell types of the human growth plate? 3. Can we perform functional studies with in vitro and ex vivo cells/explants to test the effects of current growth-promoting or -inhibiting compounds such as GH, GH-receptor antagonists and C-natriuretic peptide? To our knowledge this study would provide the first collection of biospecimen to systematically study pharmaceutical effects directly at the level of the human growth plate. The ultimate goal of this study is to form a multidisciplinary research line that will develop human growth plate models and apply molecular epidemiology such as proteomics, metabolomics, and molecular profiling (genome, transcriptome, and epigenome). This will open the way for novel models to study determinants of growth plate function and eventually medical therapies in growth disorders and several paediatric orthopaedic conditions.	—

Measure

Time frame

1. Can we harvest viable growth plate tissue from patients undergoing routine percutaneous epiphysiodesis? 2. Can we use these growth plate biopsies to make ex vivo explant cultures, perform histology, characterize molecular processes from RNA and DNA of different cell types of the human growth plate? 3. Can we perform functional studies with in vitro and ex vivo cells/explants to test the effects of current growth-promoting or -inhibiting compounds such as GH, GH-receptor antagonists and C-natriuretic peptide? To our knowledge this study would provide the first collection of biospecimen to systematically study pharmaceutical effects directly at the level of the human growth plate. The ultimate goal of this study is to form a multidisciplinary research line that will develop human growth plate models and apply molecular epidemiology such as proteomics, metabolomics, and molecular profiling (genome, transcriptome, and epigenome). This will open the way for novel models to study determinants of growth plate function and eventually medical therapies in growth disorders and several paediatric orthopaedic conditions.

—

Countries

Netherlands

Outcome results